SK Biopharmaceuticals settles first US patent dispute over Xcopri

SK Biopharmaceuticals said Wednesday it has reached a settlement with Indian generic drugmaker MSN Laboratories in a United States patent dispute over cenobamate, its epilepsy treatment sold as Xcopri in the US, laying the groundwork for continued patent protection for the drug in the world’s largest pharmaceutical market. Although the terms of the agreement were not disclosed, it marks the first resolution in SK Biopharmaceuticals’ strategy to defend Xcopri’s intellectual property rights agains

By The Korea Herald